Cervical mucus concentration of prostaglandins E2 and F2 alpha after pretreatment with mifepristone in the first trimester of pregnancy.
Cervical dilatation and softening after pretreatment with mifepristone are well documented. As this effect is similar to that observed after local application of prostaglandin E2 (PGE2) it is tempting to speculate that the effect of mifepristone is mediated via an increase of the endogenous secretion of prostaglandins from the cervical mucosa. Eighteen healthy women in the first trimester of pregnancy were treated with oral mifepristone (200 mg) 48 and 24 hours before legal abortion by vacuum aspiration and 18 women in the same age of gestation without any pretreatment served as controls. Cervical mucus was collected for measurement of prostaglandins by radioimmunoassay before administration of the drug and in connection with vacuum aspiration. The cervical dilatation at the time of surgery was significantly increased in women given mifepristone as compared with untreated women (7.6 versus 5.8 mm). The wet weight of collected cervical mucus was significantly increased in mifepristone treated women. The amount of PGE2 and prostaglandin F2 alpha per sample was unchanged in mifepristone-treated women, whereas the concentration was lower as an effect of dilution due to an increased yield in cervical secretion observed after mifepristone treatment. The present observation does not give any support to the hypothesis that mifepristone-induced cervical maturation is mediated via an increase in cervical prostaglandin production.
Bokström
H
H
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden.
Norström
A
A
Wiqvist
N
N
D000029:Abortion, Legal; D000328:Adult; D002582:Cervix Mucus / Q000737:chemistry* / Q000187:drug effects; D002584:Cervix Uteri / Q000187:drug effects / Q000502:physiology; D002690:Chlamydia Infections / Q000188:drug therapy; D002692:Chlamydia trachomatis; D004107:Dilatation and Curettage; D015237:Dinoprost / Q000032:analysis / Q000378:metabolism*; D015232:Dinoprostone / Q000032:analysis / Q000378:metabolism*; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D009325:Nausea / Q000139:chemically induced; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors; D016585:Vaginosis, Bacterial / Q000188:drug therapy
D015735:Mifepristone; D015237:Dinoprost; D015232:Dinoprostone